Results from a Phase II multicentre randomised trial, which had enrolled 67 patients, with macular telangiectasia 2, has reported meeting its primary endpoint, defined as a change in the ellipsoid zone from baseline to month 24, measured by Spectral Domain Optical Coherence Tomography (SD-OCT).